» Articles » PMID: 34386421

Long Non-Coding RNA CCAT2 Promotes the Development of Esophageal Squamous Cell Carcinoma by Inhibiting MiR-200b to Upregulate the IGF2BP2/TK1 Axis

Overview
Journal Front Oncol
Specialty Oncology
Date 2021 Aug 13
PMID 34386421
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Long non-coding RNAs (lncRNAs) have been shown to play important roles in human cancers, including esophageal squamous cell carcinoma (ESCC). In the current study, we identified CCAT2 as a relevant lncRNA and investigated its role in the progression of ESCC. RT-qPCR was adopted to detect CCAT2 expression in collected clinical samples, ESCC cell lines, and a normal cell line. We tested the correlation between CCAT2 expression and the prognosis of ESCC. RT-qPCR or immunoblotting was adopted to detect the expression of relevant factors in ESCC tissues or cells. Cell proliferation, apoptosis, migration, and invasion were examined by colony formation assay, flow cytometry, scratch assay, and Transwell assay, respectively, while subcutaneous tumorigenesis in nude mice was adopted to examine the role of CCAT2 in tumorigenesis of ESCC cells . Bioinformatics analysis, dual luciferase reporter assay, and RIP were conducted for the target relationship profiling. Me-RIP was adopted to detect m6A modification level of TK1 in ESCC tissues or cells. Upregulated CCAT2, IGF2BP2, and TK1 expression and inhibited miR-200b expression were observed in ESCC cells and tissues. CCAT2 bound to miR-200b and reduced its expression, leading to upregulated IGF2BP2 expression. IGF2BP2 improved TK1 mRNA stability to enhance its expression by recognizing its m6A modification. CCAT2 promoted the migration and invasion of ESCC cells , and tumorigenesis by upregulating TK1 expression, while overexpression of miR-200b reversed these effects of CCAT2. Overall, this study suggests that CCAT2 competitively binds to miR-200b to alleviate its inhibitory effects on IGF2BP2 expression, resulting in elevated TK1 expression, and an ensuing promotion of the development of ESCC.

Citing Articles

Multifaceted roles of insulin‑like growth factor 2 mRNA binding protein 2 in human cancer (Review).

Shen J, Ding Y Mol Med Rep. 2025; 31(3).

PMID: 39886962 PMC: 11795254. DOI: 10.3892/mmr.2025.13441.


Potential tumor-specific antigens and immune landscapes identification for mRNA vaccine in thyroid cancer.

Wang X, Wang G, Xu Q, Li Y, Song W, Liu Z Front Oncol. 2024; 14:1480028.

PMID: 39403328 PMC: 11471445. DOI: 10.3389/fonc.2024.1480028.


Readers of RNA Modification in Cancer and Their Anticancer Inhibitors.

Li F, Li W Biomolecules. 2024; 14(7).

PMID: 39062595 PMC: 11275166. DOI: 10.3390/biom14070881.


Roles of long non‑coding RNAs in esophageal cell squamous carcinoma (Review).

Yan Q, Wong W, Gong L, Yang J, Liang D, Chin K Int J Mol Med. 2024; 54(2).

PMID: 38963019 PMC: 11232667. DOI: 10.3892/ijmm.2024.5396.


The implications of N6-methyladenosine (m6A) modification in esophageal carcinoma.

He C, Teng X, Wang L, Ni M, Zhu L, Liu J Mol Biol Rep. 2023; 50(10):8691-8703.

PMID: 37598390 PMC: 10520198. DOI: 10.1007/s11033-023-08575-2.


References
1.
Zhu Y, Liu J, Fan L, Wang F, Bu L, Ma T . Serum expression and significance of MicroRNA-30d-5p in esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2020; 10(8):8677-8685. PMC: 6965463. View

2.
Zhang L, Sanagapalli S, Stoita A . Challenges in diagnosis of pancreatic cancer. World J Gastroenterol. 2018; 24(19):2047-2060. PMC: 5960811. DOI: 10.3748/wjg.v24.i19.2047. View

3.
Domper Arnal M, Ferrandez Arenas A, Lanas Arbeloa A . Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol. 2015; 21(26):7933-43. PMC: 4499337. DOI: 10.3748/wjg.v21.i26.7933. View

4.
Zhang H, Alshareef A, Wu C, Li S, Jiao J, Cao H . Loss of miR-200b promotes invasion via activating the Kindlin-2/integrin β1/AKT pathway in esophageal squamous cell carcinoma: An E-cadherin-independent mechanism. Oncotarget. 2015; 6(30):28949-60. PMC: 4745703. DOI: 10.18632/oncotarget.5027. View

5.
Bi Z, Liu Y, Zhao Y, Yao Y, Wu R, Liu Q . A dynamic reversible RNA N -methyladenosine modification: current status and perspectives. J Cell Physiol. 2019; 234(6):7948-7956. DOI: 10.1002/jcp.28014. View